Artwork

Content provided by Bryn Mawr Communications (BMC) and Retina Today. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Bryn Mawr Communications (BMC) and Retina Today or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

ARVO '25: Real-World Next-Gen Anti-VEGF Dosing and TKIs in the Pipeline

22:47
 
Share
 

Manage episode 484232640 series 2134816
Content provided by Bryn Mawr Communications (BMC) and Retina Today. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Bryn Mawr Communications (BMC) and Retina Today or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

Next-generation anti-VEGF agents are designed for durability. But does that actually change the rate at which they’re administered? David Miller, MD, joins us to review a pair of ARVO 2025 presentations that examined his clinic’s real-world administration patterns for bevacizumab (Avastin, Genentech), faricimab (Vabysmo, Genentech/Roche), and high-dose aflibercept (Eylea HD, Regeneron). What were the differences—and did they really matter? Also, Robert Wang, MD, helped us understand the state of play in the TKI pipeline as he shared data from the phase 2b ODYSSEY study. What are the latest data on CLX-AX (Clearside Biomedcial)? And where does it stack up against the other TKIs in the pipeline? Stick with us to find out.

  continue reading

194 episodes

Artwork
iconShare
 
Manage episode 484232640 series 2134816
Content provided by Bryn Mawr Communications (BMC) and Retina Today. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Bryn Mawr Communications (BMC) and Retina Today or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

Next-generation anti-VEGF agents are designed for durability. But does that actually change the rate at which they’re administered? David Miller, MD, joins us to review a pair of ARVO 2025 presentations that examined his clinic’s real-world administration patterns for bevacizumab (Avastin, Genentech), faricimab (Vabysmo, Genentech/Roche), and high-dose aflibercept (Eylea HD, Regeneron). What were the differences—and did they really matter? Also, Robert Wang, MD, helped us understand the state of play in the TKI pipeline as he shared data from the phase 2b ODYSSEY study. What are the latest data on CLX-AX (Clearside Biomedcial)? And where does it stack up against the other TKIs in the pipeline? Stick with us to find out.

  continue reading

194 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide

Listen to this show while you explore
Play